☆ 4.3 Article

Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.

OPHTHALMIC RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article Ophthalmology

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser

Richard Gale et al.

Summary: Real-world data from 27 National Health Service Trusts in the UK showed that anti-vascular endothelial growth factor was more effective in treating macular oedema secondary to branch retinal vein occlusion compared to intravitreal dexamethasone, with sustained visual acuity improvements. Patients in the anti-VEGF group had higher visual acuity improvements at different time points, and the treatment burden reduced over time.

BRITISH JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections

Richard Gale et al.

Summary: This study aimed to evaluate the efficacy, burden, and safety of two treatment categories for CRVO. The findings indicated that anti-VEGF treatment led to greater and more sustained improvements in VA, while Ozurdex treatment was associated with higher rates of endophthalmitis.

BRITISH JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Raja Narayanan et al.

Summary: The study showed that ranibizumab is well tolerated and effective in treating macular edema secondary to retinal vein occlusion in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment.

BMC OPHTHALMOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach

D. Yu. Khokhlova et al.

Summary: This study aimed to establish morphological and functional parameters to predict the effectiveness of IVI of ranibizumab in treating macular edema, and to develop a mathematical model for personalized treatment algorithms. The results showed that baseline morphological and functional changes significantly affect the efficacy of IVI, and the mathematical model obtained can predict treatment outcomes and guide personalized therapy.

EPMA JOURNAL (2021)

Add to Collection

Article Ophthalmology

Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion

Piyali Sen et al.

Summary: This study evaluated the impact of baseline characteristics on visual outcomes in patients receiving anti-VEGF therapy for ME caused by CRVO. Results showed that age ≥75 years was a poor predictor for visual outcomes, while lower baseline BCVA predicted 10-letter gainers and higher gains in BCVA, but not achieving >70 letters in BCVA.

OPHTHALMOLOGY RETINA (2021)

Add to Collection

Article Ophthalmology

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Kimberly Spooner et al.

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study

Ian Pearce et al.

PLOS ONE (2020)

Add to Collection

Article Ophthalmology

Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion

Glenn Yiu et al.

OPHTHALMOLOGY RETINA (2020)

Add to Collection

Review Public, Environmental & Occupational Health

Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors

Peige Song et al.

JOURNAL OF GLOBAL HEALTH (2019)

Add to Collection

Article Ophthalmology

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study

Josep Callizo et al.

CLINICAL OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

Maria Eleftheriadou et al.

OPHTHALMOLOGY AND THERAPY (2019)

Add to Collection

Article Ophthalmology

Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)

Ursula Schmidt-Erfurth et al.

OPHTHALMOLOGICA (2019)

Add to Collection

Article Ophthalmology

Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result

P. L. Lip et al.

EYE (2018)

Add to Collection

Article Ophthalmology

Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors

Maria-Magdalena Guichard et al.

OPHTHALMIC RESEARCH (2018)

Add to Collection

Article Ophthalmology

Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study

Michael Larsen et al.

OPHTHALMOLOGY RETINA (2018)

Add to Collection

Article Ophthalmology

Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal

Sara Vaz-Pereira et al.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion

Ramin Tadayoni et al.

OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Treat-and-Extend Regimen for Macular Edema Secondary to Central Retinal Vein Occlusion: 12-Month Results

Ehsan Rahimy et al.

OPHTHALMOLOGY RETINA (2017)

Add to Collection

Review Ophthalmology

Central retinal vein occlusion: modifying current treatment protocols

M. Ashraf et al.

EYE (2016)

Add to Collection

Article Ophthalmology

RANIBIZUMAB IN PREPROLIFERATIVE (ISCHEMIC) CENTRAL RETINAL VEIN OCCLUSION The Rubeosis Anti-VEGF (RAVE) Trial

David M. Brown et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)

Add to Collection

Article Ophthalmology

Ranibizumab for Macular Edema Due to Retinal Vein Occlusions Long-term Follow-up in the HORIZON Trial

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2012)

Add to Collection

Review Ophthalmology

Treatment of macular edema due to retinal vein occlusions

Roomasa Channa et al.

CLINICAL OPHTHALMOLOGY (2011)

Add to Collection

Article Ophthalmology

Obstructive Sleep Apnea Among Patients With Retinal Vein Occlusion

Agnes Glacet-Bernard et al.

ARCHIVES OF OPHTHALMOLOGY (2010)

Add to Collection

Article Ophthalmology

Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study

Peter A. Campochiaro et al.

OPHTHALMOLOGY (2010)

Add to Collection

Article Ophthalmology

Ranibizumab for Macular Edema following Central Retinal Vein Occlusion

David M. Brown et al.

OPHTHALMOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.